SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '6UI'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1IEP_A_STIA201_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 40 VAL A 48 ALA A 61 PHE A 110 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.95A	1iepA-4usfA: 18.8	1iepA-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1IEP_A_STIA201_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	VAL A 48 ALA A 61 PHE A 110 GLY A 114 LEU A 162 ALA A 172 ASP A 173	None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	1.14A	1iepA-4usfA: 18.8	1iepA-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1IEP_B_STIB202_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 40 VAL A 48 ALA A 61 PHE A 110 GLY A 114 ALA A 172 ASP A 173	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 ( 4.1A) None	1.16A	1iepB-4usfA: 18.9	1iepB-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XBB_A_STIA1_1 (TYROSINE-PROTEIN KINASE SYK)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 9	LEU A 40 VAL A 48 ALA A 61 GLY A 114 LEU A 162	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	0.41A	1xbbA-4usfA: 23.6	1xbbA-4usfA: 24.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2GQG_A_1N1A501_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	LEU A 40 ALA A 61 VAL A 92 ILE A 106 PHE A 110 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) 6UI A 700 (-3.3A) None 6UI A 700 (-3.5A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.68A	2gqgA-4usfA: 17.9	2gqgA-4usfA: 27.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_A_STIA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	VAL A 48 ALA A 61 PHE A 110 GLY A 114 LEU A 162 ALA A 172 ASP A 173	None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	1.10A	2hyyA-4usfA: 18.9	2hyyA-4usfA: 28.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_B_STIB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	VAL A 48 ALA A 61 PHE A 110 GLY A 114 LEU A 162 ALA A 172 ASP A 173	None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	1.14A	2hyyB-4usfA: 18.8	2hyyB-4usfA: 28.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_C_STIC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	VAL A 48 ALA A 61 VAL A 92 PHE A 110 GLY A 114 LEU A 162 ALA A 172 ASP A 173	None 6UI A 700 (-3.3A) None 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	0.97A	2hyyC-4usfA: 25.0	2hyyC-4usfA: 28.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_D_STID600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	VAL A 48 ALA A 61 ILE A 106 PHE A 110 LEU A 162 ALA A 172	None 6UI A 700 (-3.3A) 6UI A 700 (-3.5A) 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.89A	2hyyD-4usfA: 18.8	2hyyD-4usfA: 28.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_D_STID600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	VAL A 48 ALA A 61 PHE A 110 LEU A 162 ALA A 172 ASP A 173	None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	1.11A	2hyyD-4usfA: 18.8	2hyyD-4usfA: 28.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 40 ALA A 61 VAL A 92 ILE A 106 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) 6UI A 700 (-3.3A) None 6UI A 700 (-3.5A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.72A	2zvaA-4usfA: 19.2	2zvaA-4usfA: 26.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3C7Q_A_XINA1172_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 40 GLY A 41 ALA A 61 PHE A 110 CYH A 111 GLY A 114 LEU A 162	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	1.15A	3c7qA-4usfA: 18.0	3c7qA-4usfA: 27.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 10	LEU A 40 VAL A 48 VAL A 92 ILE A 106 PHE A 110	6UI A 700 ( 4.9A) None None 6UI A 700 (-3.5A) 6UI A 700 (-4.3A)	0.75A	3cs9A-4usfA: 18.5	3cs9A-4usfA: 28.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_B_NILB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 12	ALA A 61 GLY A 114 HIS A 153 ALA A 172 ASP A 173	6UI A 700 (-3.3A) 6UI A 700 ( 4.2A) None 6UI A 700 ( 4.1A) None	0.83A	3cs9B-4usfA: 19.7	3cs9B-4usfA: 28.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_C_NILC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 9	LEU A 40 VAL A 48 LYS A 63 VAL A 92 ILE A 106	6UI A 700 ( 4.9A) None 6UI A 700 (-4.5A) None 6UI A 700 (-3.5A)	1.02A	3cs9C-4usfA: 24.4	3cs9C-4usfA: 28.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3GVU_A_STIA1001_1 (TYROSINE-PROTEIN KINASE ABL2)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 40 VAL A 48 ALA A 61 VAL A 92 LEU A 162 ALA A 172 ASP A 173	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) None 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	0.93A	3gvuA-4usfA: 18.9	3gvuA-4usfA: 28.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IK3_A_0LIA1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	ALA A 61 VAL A 92 HIS A 153 LEU A 162 ALA A 172 ASP A 173	6UI A 700 (-3.3A) None None 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	0.72A	3ik3A-4usfA: 24.7	3ik3A-4usfA: 29.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IK3_B_0LIB2_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	ALA A 61 VAL A 92 HIS A 153 LEU A 162 ALA A 172 ASP A 173	6UI A 700 (-3.3A) None None 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	0.73A	3ik3B-4usfA: 24.4	3ik3B-4usfA: 29.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3K5V_A_STIA2_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	VAL A 48 ALA A 61 PHE A 110 GLY A 114 LEU A 162 ALA A 172 ASP A 173	None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	1.15A	3k5vA-4usfA: 23.9	3k5vA-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3K5V_B_STIB2_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	VAL A 48 ALA A 61 PHE A 110 GLY A 114 LEU A 162 ALA A 172 ASP A 173	None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	1.11A	3k5vB-4usfA: 18.2	3k5vB-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MIY_B_B49B2_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 9	ALA A 61 LYS A 63 PHE A 110 GLY A 114 LEU A 162	6UI A 700 (-3.3A) 6UI A 700 (-4.5A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	0.69A	3miyB-4usfA: 24.8	3miyB-4usfA: 26.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MS9_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	LEU A 40 VAL A 48 ALA A 61 PHE A 110 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.80A	3ms9A-4usfA: 18.9	3ms9A-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MS9_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	VAL A 48 ALA A 61 PHE A 110 LEU A 162 ALA A 172 ASP A 173	None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	1.11A	3ms9A-4usfA: 18.9	3ms9A-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MS9_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 40 VAL A 48 ALA A 61 PHE A 110 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.91A	3ms9B-4usfA: 18.8	3ms9B-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MS9_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	VAL A 48 ALA A 61 PHE A 110 GLY A 114 LEU A 162 ALA A 172 ASP A 173	None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	1.13A	3ms9B-4usfA: 18.8	3ms9B-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	LEU A 40 VAL A 48 ALA A 61 PHE A 110 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.83A	3mssA-4usfA: 19.0	3mssA-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_A_STIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	VAL A 48 ALA A 61 PHE A 110 LEU A 162 ALA A 172 ASP A 173	None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	1.11A	3mssA-4usfA: 19.0	3mssA-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_C_STIC1_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	LEU A 40 VAL A 48 ALA A 61 PHE A 110 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.83A	3mssC-4usfA: 19.0	3mssC-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_C_STIC1_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	VAL A 48 ALA A 61 PHE A 110 LEU A 162 ALA A 172 ASP A 173	None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	1.12A	3mssC-4usfA: 19.0	3mssC-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_D_STID1_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	ALA A 61 PHE A 110 GLY A 114 LEU A 162 ALA A 172 ASP A 173	6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	0.91A	3mssD-4usfA: 19.0	3mssD-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_D_STID1_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	LEU A 40 ALA A 61 PHE A 110 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.92A	3mssD-4usfA: 19.0	3mssD-4usfA: 28.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OEZ_A_STIA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	VAL A 48 ALA A 61 VAL A 92 GLY A 114 LEU A 162 ALA A 172 ASP A 173	None 6UI A 700 (-3.3A) None 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	0.73A	3oezA-4usfA: 19.1	3oezA-4usfA: 26.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OXZ_A_0LIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	ALA A 61 VAL A 92 GLY A 114 HIS A 153 ALA A 172 ASP A 173	6UI A 700 (-3.3A) None 6UI A 700 ( 4.2A) None 6UI A 700 ( 4.1A) None	0.79A	3oxzA-4usfA: 23.6	3oxzA-4usfA: 27.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 40 ALA A 61 LYS A 63 VAL A 92 ILE A 106 PHE A 110 LEU A 162	6UI A 700 ( 4.9A) 6UI A 700 (-3.3A) 6UI A 700 (-4.5A) None 6UI A 700 (-3.5A) 6UI A 700 (-4.3A) 6UI A 700 (-4.2A)	0.76A	3ue4A-4usfA: 17.7	3ue4A-4usfA: 29.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 40 ALA A 61 VAL A 92 ILE A 106 PHE A 110 GLY A 114 LEU A 162	6UI A 700 ( 4.9A) 6UI A 700 (-3.3A) None 6UI A 700 (-3.5A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	0.58A	3ue4A-4usfA: 17.7	3ue4A-4usfA: 29.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UE4_B_DB8B601_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	LEU A 40 VAL A 48 ALA A 61 VAL A 92 ILE A 106 PHE A 110 GLY A 114 LEU A 162	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) None 6UI A 700 (-3.5A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	0.68A	3ue4B-4usfA: 23.7	3ue4B-4usfA: 29.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZE_A_BAXA1201_2 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 8	VAL A 92 CYH A 111 LEU A 162 ASP A 173	None 6UI A 700 (-4.2A) 6UI A 700 (-4.2A) None	0.54A	3wzeA-4usfA: 18.0	3wzeA-4usfA: 28.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 11	ALA A 61 VAL A 92 PHE A 110 CYH A 111 GLY A 114 LEU A 162	6UI A 700 (-3.3A) None 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	0.64A	4agdA-4usfA: 21.6	4agdA-4usfA: 25.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 11	LEU A 40 ALA A 61 LYS A 63 PHE A 110 GLY A 114 LEU A 162	6UI A 700 ( 4.9A) 6UI A 700 (-3.3A) 6UI A 700 (-4.5A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	1.02A	4agdA-4usfA: 21.6	4agdA-4usfA: 25.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 11	LEU A 40 ALA A 61 PHE A 110 CYH A 111 GLY A 114 LEU A 162	6UI A 700 ( 4.9A) 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	0.70A	4agdA-4usfA: 21.6	4agdA-4usfA: 25.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ANQ_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 9	LEU A 40 VAL A 48 ALA A 61 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.56A	4anqA-4usfA: 23.6	4anqA-4usfA: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ANS_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 9	LEU A 40 VAL A 48 ALA A 61 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.56A	4ansA-4usfA: 23.5	4ansA-4usfA: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXX_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 40 VAL A 48 ALA A 61 LYS A 63 VAL A 92 GLY A 114 LEU A 162	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 (-4.5A) None 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	0.77A	4mxxB-4usfA: 17.8	4mxxB-4usfA: 25.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXY_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 40 VAL A 48 ALA A 61 VAL A 92 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) None 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.56A	4mxyB-4usfA: 17.7	4mxyB-4usfA: 26.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4MXZ_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 40 VAL A 48 ALA A 61 VAL A 92 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) None 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.56A	4mxzB-4usfA: 17.7	4mxzB-4usfA: 26.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4O0U_A_ADNA501_1 (AURORA KINASE A)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 6	VAL A 48 ALA A 61 LYS A 63 LEU A 162	None 6UI A 700 (-3.3A) 6UI A 700 (-4.5A) 6UI A 700 (-4.2A)	0.76A	4o0uA-4usfA: 19.6	4o0uA-4usfA: 30.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OTW_A_DB8A1101_1 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 40 VAL A 48 LYS A 63 VAL A 92 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-4.5A) None 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.81A	4otwA-4usfA: 17.3	4otwA-4usfA: 27.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4TWP_B_AXIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	LEU A 40 VAL A 48 ALA A 61 PHE A 110 GLY A 114 ASN A 160 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) None 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	1.02A	4twpB-4usfA: 18.3	4twpB-4usfA: 28.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4UXQ_A_0LIA1752_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	ALA A 61 LEU A 146 HIS A 153 LEU A 162 ALA A 172 ASP A 173	6UI A 700 (-3.3A) None None 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	0.93A	4uxqA-4usfA: 18.3	4uxqA-4usfA: 27.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 11	LEU A 40 ALA A 61 GLY A 114 ASN A 160 LEU A 162 ALA A 172 PHE A 174	6UI A 700 ( 4.9A) 6UI A 700 (-3.3A) 6UI A 700 ( 4.2A) None 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	1.01A	4wa9A-4usfA: 21.5	4wa9A-4usfA: 29.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	ALA A 61 PHE A 110 GLY A 114 ASN A 160 LEU A 162 ALA A 172 PHE A 174	6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) None 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	1.31A	4wa9B-4usfA: 18.0	4wa9B-4usfA: 29.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	VAL A 48 ALA A 61 PHE A 110 GLY A 114 ASN A 160 LEU A 162 ALA A 172	None 6UI A 700 (-3.3A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) None 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	1.04A	4wa9B-4usfA: 18.0	4wa9B-4usfA: 29.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XEY_A_1N1A601_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	LEU A 40 VAL A 48 ALA A 61 LYS A 63 VAL A 92 ILE A 106 PHE A 110 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 (-4.5A) None 6UI A 700 (-3.5A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.90A	4xeyA-4usfA: 17.5	4xeyA-4usfA: 25.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XEY_B_1N1B601_1 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	10 / 12	LEU A 40 VAL A 48 ALA A 61 LYS A 63 VAL A 92 ILE A 106 PHE A 110 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 (-4.5A) None 6UI A 700 (-3.5A) 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.86A	4xeyB-4usfA: 16.3	4xeyB-4usfA: 25.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AJQ_A_DB8A800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	LEU A 40 GLY A 41 ALA A 61 LYS A 63 PHE A 110 CYH A 111 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 (-4.5A) 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.78A	5ajqA-4usfA: 36.2	5ajqA-4usfA: 75.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_C_1N1C501_1 (PROTEIN-TYROSINE KINASE 6)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 12	LEU A 40 ALA A 61 ILE A 106 GLY A 114 LEU A 162	6UI A 700 ( 4.9A) 6UI A 700 (-3.3A) 6UI A 700 (-3.5A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	0.55A	5h2uC-4usfA: 17.7	5h2uC-4usfA: 27.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	LEU A 40 VAL A 48 ALA A 61 ILE A 106 GLY A 114 LEU A 162	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 (-3.5A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	0.57A	5h2uD-4usfA: 17.7	5h2uD-4usfA: 27.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	ALA A 61 VAL A 92 HIS A 153 LEU A 162 ALA A 172 ASP A 173	6UI A 700 (-3.3A) None None 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	0.69A	5mo4A-4usfA: 14.8	5mo4A-4usfA: 20.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5P9I_A_1E8A701_1 (TYROSINE-PROTEIN KINASE BTK)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	VAL A 48 ALA A 61 LYS A 63 ILE A 106 GLY A 114 LEU A 162	None 6UI A 700 (-3.3A) 6UI A 700 (-4.5A) 6UI A 700 (-3.5A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A)	0.81A	5p9iA-4usfA: 18.2	5p9iA-4usfA: 26.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD6_A_STIA603_0 (TYROSINE-PROTEIN KINASE ABL1)	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	VAL A 48 ALA A 61 VAL A 92 ILE A 106 PHE A 110 LEU A 162 ALA A 172	None 6UI A 700 (-3.3A) None 6UI A 700 (-3.5A) 6UI A 700 (-4.3A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.95A	6hd6A-4usfA: 23.9	6hd6A-4usfA: 12.45

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1IEP_A_STIA201_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A  40;VAL A  48;ALA A  61;PHE A 110;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.95A","1iepA-4usfA:18.8",null],["1IEP_A_STIA201_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"VAL A  48;ALA A  61;PHE A 110;GLY A 114;LEU A 162;ALA A 172;ASP A 173","None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","1.14A","1iepA-4usfA:18.8","1iepA-4usfA:28.26"],["1IEP_B_STIB202_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A  40;VAL A  48;ALA A  61;PHE A 110;GLY A 114;ALA A 172;ASP A 173","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 ( 4.1A);None","1.16A","1iepB-4usfA:18.9","1iepA-4usfA:28.26"],["1XBB_A_STIA1_1","TYROSINE-PROTEIN KINASE SYK","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"LEU A  40;VAL A  48;ALA A  61;GLY A 114;LEU A 162","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","0.41A","1xbbA-4usfA:23.6","1iepB-4usfA:28.26"],["2GQG_A_1N1A501_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"LEU A  40;ALA A  61;VAL A  92;ILE A 106;PHE A 110;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);6UI A 700 (-3.3A);None;6UI A 700 (-3.5A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.68A","2gqgA-4usfA:17.9","1xbbA-4usfA:24.53"],["2HYY_A_STIA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"VAL A  48;ALA A  61;PHE A 110;GLY A 114;LEU A 162;ALA A 172;ASP A 173","None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","1.10A","2hyyA-4usfA:18.9","2gqgA-4usfA:27.50"],["2HYY_B_STIB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"VAL A  48;ALA A  61;PHE A 110;GLY A 114;LEU A 162;ALA A 172;ASP A 173","None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","1.14A","2hyyB-4usfA:18.8","2hyyA-4usfA:28.00"],["2HYY_C_STIC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"VAL A  48;ALA A  61;VAL A  92;PHE A 110;GLY A 114;LEU A 162;ALA A 172;ASP A 173","None;6UI A 700 (-3.3A);None;6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","0.97A","2hyyC-4usfA:25.0","2hyyB-4usfA:28.00"],["2HYY_D_STID600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"VAL A  48;ALA A  61;ILE A 106;PHE A 110;LEU A 162;ALA A 172","None;6UI A 700 (-3.3A);6UI A 700 (-3.5A);6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.89A","2hyyD-4usfA:18.8","2hyyC-4usfA:28.00"],["2HYY_D_STID600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"VAL A  48;ALA A  61;PHE A 110;LEU A 162;ALA A 172;ASP A 173","None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","1.11A","2hyyD-4usfA:18.8","2hyyD-4usfA:28.00"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A  40;ALA A  61;VAL A  92;ILE A 106;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);6UI A 700 (-3.3A);None;6UI A 700 (-3.5A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.72A","2zvaA-4usfA:19.2","2hyyD-4usfA:28.00"],["3C7Q_A_XINA1172_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A  40;GLY A  41;ALA A  61;PHE A 110;CYH A 111;GLY A 114;LEU A 162","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","1.15A","3c7qA-4usfA:18.0","2zvaA-4usfA:26.17"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"LEU A  40;VAL A  48;VAL A  92;ILE A 106;PHE A 110","6UI A 700 ( 4.9A);None;None;6UI A 700 (-3.5A);6UI A 700 (-4.3A)","0.75A","3cs9A-4usfA:18.5","3c7qA-4usfA:27.75"],["3CS9_B_NILB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"ALA A  61;GLY A 114;HIS A 153;ALA A 172;ASP A 173","6UI A 700 (-3.3A);6UI A 700 ( 4.2A);None;6UI A 700 ( 4.1A);None","0.83A","3cs9B-4usfA:19.7","3cs9A-4usfA:28.22"],["3CS9_C_NILC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"LEU A  40;VAL A  48;LYS A  63;VAL A  92;ILE A 106","6UI A 700 ( 4.9A);None;6UI A 700 (-4.5A);None;6UI A 700 (-3.5A)","1.02A","3cs9C-4usfA:24.4","3cs9B-4usfA:28.22"],["3GVU_A_STIA1001_1","TYROSINE-PROTEIN KINASE ABL2","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A  40;VAL A  48;ALA A  61;VAL A  92;LEU A 162;ALA A 172;ASP A 173","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);None;6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","0.93A","3gvuA-4usfA:18.9","3cs9C-4usfA:28.22"],["3IK3_A_0LIA1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"ALA A  61;VAL A  92;HIS A 153;LEU A 162;ALA A 172;ASP A 173","6UI A 700 (-3.3A);None;None;6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","0.72A","3ik3A-4usfA:24.7","3gvuA-4usfA:28.18"],["3IK3_B_0LIB2_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"ALA A  61;VAL A  92;HIS A 153;LEU A 162;ALA A 172;ASP A 173","6UI A 700 (-3.3A);None;None;6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","0.73A","3ik3B-4usfA:24.4","3ik3A-4usfA:29.05"],["3K5V_A_STIA2_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"VAL A  48;ALA A  61;PHE A 110;GLY A 114;LEU A 162;ALA A 172;ASP A 173","None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","1.15A","3k5vA-4usfA:23.9","3ik3B-4usfA:29.05"],["3K5V_B_STIB2_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"VAL A  48;ALA A  61;PHE A 110;GLY A 114;LEU A 162;ALA A 172;ASP A 173","None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","1.11A","3k5vB-4usfA:18.2","3k5vA-4usfA:28.26"],["3MIY_B_B49B2_1","TYROSINE-PROTEIN KINASE ITK\/TSK","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"ALA A  61;LYS A  63;PHE A 110;GLY A 114;LEU A 162","6UI A 700 (-3.3A);6UI A 700 (-4.5A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","0.69A","3miyB-4usfA:24.8","3k5vB-4usfA:28.26"],["3MS9_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A  40;VAL A  48;ALA A  61;PHE A 110;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.80A","3ms9A-4usfA:18.9","3miyB-4usfA:26.92"],["3MS9_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"VAL A  48;ALA A  61;PHE A 110;LEU A 162;ALA A 172;ASP A 173","None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","1.11A","3ms9A-4usfA:18.9","3ms9A-4usfA:28.26"],["3MS9_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A  40;VAL A  48;ALA A  61;PHE A 110;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.91A","3ms9B-4usfA:18.8","3ms9A-4usfA:28.26"],["3MS9_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"VAL A  48;ALA A  61;PHE A 110;GLY A 114;LEU A 162;ALA A 172;ASP A 173","None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","1.13A","3ms9B-4usfA:18.8","3ms9B-4usfA:28.26"],["3MSS_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A  40;VAL A  48;ALA A  61;PHE A 110;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.83A","3mssA-4usfA:19.0","3ms9B-4usfA:28.26"],["3MSS_A_STIA1_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"VAL A  48;ALA A  61;PHE A 110;LEU A 162;ALA A 172;ASP A 173","None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","1.11A","3mssA-4usfA:19.0","3mssA-4usfA:28.26"],["3MSS_C_STIC1_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A  40;VAL A  48;ALA A  61;PHE A 110;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.83A","3mssC-4usfA:19.0","3mssA-4usfA:28.26"],["3MSS_C_STIC1_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"VAL A  48;ALA A  61;PHE A 110;LEU A 162;ALA A 172;ASP A 173","None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","1.12A","3mssC-4usfA:19.0","3mssC-4usfA:28.26"],["3MSS_D_STID1_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"ALA A  61;PHE A 110;GLY A 114;LEU A 162;ALA A 172;ASP A 173","6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","0.91A","3mssD-4usfA:19.0","3mssC-4usfA:28.26"],["3MSS_D_STID1_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A  40;ALA A  61;PHE A 110;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.92A","3mssD-4usfA:19.0","3mssD-4usfA:28.26"],["3OEZ_A_STIA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"VAL A  48;ALA A  61;VAL A  92;GLY A 114;LEU A 162;ALA A 172;ASP A 173","None;6UI A 700 (-3.3A);None;6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","0.73A","3oezA-4usfA:19.1","3mssD-4usfA:28.26"],["3OXZ_A_0LIA1_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"ALA A  61;VAL A  92;GLY A 114;HIS A 153;ALA A 172;ASP A 173","6UI A 700 (-3.3A);None;6UI A 700 ( 4.2A);None;6UI A 700 ( 4.1A);None","0.79A","3oxzA-4usfA:23.6","3oezA-4usfA:26.50"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A  40;ALA A  61;LYS A  63;VAL A  92;ILE A 106;PHE A 110;LEU A 162","6UI A 700 ( 4.9A);6UI A 700 (-3.3A);6UI A 700 (-4.5A);None;6UI A 700 (-3.5A);6UI A 700 (-4.3A);6UI A 700 (-4.2A)","0.76A","3ue4A-4usfA:17.7","3oxzA-4usfA:27.98"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A  40;ALA A  61;VAL A  92;ILE A 106;PHE A 110;GLY A 114;LEU A 162","6UI A 700 ( 4.9A);6UI A 700 (-3.3A);None;6UI A 700 (-3.5A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","0.58A","3ue4A-4usfA:17.7","3ue4A-4usfA:29.14"],["3UE4_B_DB8B601_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"LEU A  40;VAL A  48;ALA A  61;VAL A  92;ILE A 106;PHE A 110;GLY A 114;LEU A 162","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);None;6UI A 700 (-3.5A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","0.68A","3ue4B-4usfA:23.7","3ue4A-4usfA:29.14"],["3WZE_A_BAXA1201_2","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"VAL A  92;CYH A 111;LEU A 162;ASP A 173","None;6UI A 700 (-4.2A);6UI A 700 (-4.2A);None","0.54A","3wzeA-4usfA:18.0","3ue4B-4usfA:29.14"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"ALA A  61;VAL A  92;PHE A 110;CYH A 111;GLY A 114;LEU A 162","6UI A 700 (-3.3A);None;6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","0.64A","4agdA-4usfA:21.6","3wzeA-4usfA:28.20"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A  40;ALA A  61;LYS A  63;PHE A 110;GLY A 114;LEU A 162","6UI A 700 ( 4.9A);6UI A 700 (-3.3A);6UI A 700 (-4.5A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","1.02A","4agdA-4usfA:21.6","4agdA-4usfA:25.78"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A  40;ALA A  61;PHE A 110;CYH A 111;GLY A 114;LEU A 162","6UI A 700 ( 4.9A);6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","0.70A","4agdA-4usfA:21.6","4agdA-4usfA:25.78"],["4ANQ_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A  40;VAL A  48;ALA A  61;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.56A","4anqA-4usfA:23.6","4agdA-4usfA:25.78"],["4ANS_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A  40;VAL A  48;ALA A  61;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.56A","4ansA-4usfA:23.5","4anqA-4usfA:28.57"],["4MXX_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A  40;VAL A  48;ALA A  61;LYS A  63;VAL A  92;GLY A 114;LEU A 162","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 (-4.5A);None;6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","0.77A","4mxxB-4usfA:17.8","4ansA-4usfA:28.57"],["4MXY_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A  40;VAL A  48;ALA A  61;VAL A  92;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);None;6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.56A","4mxyB-4usfA:17.7","4mxxB-4usfA:25.63"],["4MXZ_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A  40;VAL A  48;ALA A  61;VAL A  92;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);None;6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.56A","4mxzB-4usfA:17.7","4mxyB-4usfA:26.27"],["4O0U_A_ADNA501_1","AURORA KINASE A","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"VAL A  48;ALA A  61;LYS A  63;LEU A 162","None;6UI A 700 (-3.3A);6UI A 700 (-4.5A);6UI A 700 (-4.2A)","0.76A","4o0uA-4usfA:19.6","4mxzB-4usfA:26.27"],["4OTW_A_DB8A1101_1","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A  40;VAL A  48;LYS A  63;VAL A  92;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-4.5A);None;6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.81A","4otwA-4usfA:17.3","4o0uA-4usfA:30.55"],["4TWP_B_AXIB601_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"LEU A  40;VAL A  48;ALA A  61;PHE A 110;GLY A 114;ASN A 160;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);None;6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","1.02A","4twpB-4usfA:18.3","4otwA-4usfA:27.13"],["4UXQ_A_0LIA1752_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"ALA A  61;LEU A 146;HIS A 153;LEU A 162;ALA A 172;ASP A 173","6UI A 700 (-3.3A);None;None;6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","0.93A","4uxqA-4usfA:18.3","4twpB-4usfA:28.04"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A  40;ALA A  61;GLY A 114;ASN A 160;LEU A 162;ALA A 172;PHE A 174","6UI A 700 ( 4.9A);6UI A 700 (-3.3A);6UI A 700 ( 4.2A);None;6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","1.01A","4wa9A-4usfA:21.5","4uxqA-4usfA:27.43"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"ALA A  61;PHE A 110;GLY A 114;ASN A 160;LEU A 162;ALA A 172;PHE A 174","6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);None;6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","1.31A","4wa9B-4usfA:18.0","4wa9A-4usfA:29.14"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"VAL A  48;ALA A  61;PHE A 110;GLY A 114;ASN A 160;LEU A 162;ALA A 172","None;6UI A 700 (-3.3A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);None;6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","1.04A","4wa9B-4usfA:18.0","4wa9B-4usfA:29.14"],["4XEY_A_1N1A601_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"LEU A  40;VAL A  48;ALA A  61;LYS A  63;VAL A  92;ILE A 106;PHE A 110;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 (-4.5A);None;6UI A 700 (-3.5A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.90A","4xeyA-4usfA:17.5","4wa9B-4usfA:29.14"],["4XEY_B_1N1B601_1","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",10,"LEU A  40;VAL A  48;ALA A  61;LYS A  63;VAL A  92;ILE A 106;PHE A 110;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 (-4.5A);None;6UI A 700 (-3.5A);6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.86A","4xeyB-4usfA:16.3","4xeyA-4usfA:25.71"],["5AJQ_A_DB8A800_1","SERINE\/THREONINE-PROTEIN KINASE 10","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"LEU A  40;GLY A  41;ALA A  61;LYS A  63;PHE A 110;CYH A 111;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 (-4.5A);6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.78A","5ajqA-4usfA:36.2","4xeyB-4usfA:25.71"],["5H2U_C_1N1C501_1","PROTEIN-TYROSINE KINASE 6","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"LEU A  40;ALA A  61;ILE A 106;GLY A 114;LEU A 162","6UI A 700 ( 4.9A);6UI A 700 (-3.3A);6UI A 700 (-3.5A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","0.55A","5h2uC-4usfA:17.7","5ajqA-4usfA:75.59"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A  40;VAL A  48;ALA A  61;ILE A 106;GLY A 114;LEU A 162","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 (-3.5A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","0.57A","5h2uD-4usfA:17.7","5h2uC-4usfA:27.62"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"ALA A  61;VAL A  92;HIS A 153;LEU A 162;ALA A 172;ASP A 173","6UI A 700 (-3.3A);None;None;6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","0.69A","5mo4A-4usfA:14.8","5h2uD-4usfA:27.62"],["5P9I_A_1E8A701_1","TYROSINE-PROTEIN KINASE BTK","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"VAL A  48;ALA A  61;LYS A  63;ILE A 106;GLY A 114;LEU A 162","None;6UI A 700 (-3.3A);6UI A 700 (-4.5A);6UI A 700 (-3.5A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A)","0.81A","5p9iA-4usfA:18.2","5mo4A-4usfA:20.58"],["6HD6_A_STIA603_0","TYROSINE-PROTEIN KINASE ABL1","4usf","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"VAL A  48;ALA A  61;VAL A  92;ILE A 106;PHE A 110;LEU A 162;ALA A 172","None;6UI A 700 (-3.3A);None;6UI A 700 (-3.5A);6UI A 700 (-4.3A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.95A","6hd6A-4usfA:23.9","5p9iA-4usfA:26.52"]]